MedTrace Logo

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-06-09

Study results available
· View outcomes & findings →

Summary

Purpose of the study is to determine if Cimzia is safe and effective in subjects who have received previous treatment with a TNF-alpha inhibitor other than Cimzia.

Conditions

Interventions

DRUG

Cimzia

prefilled 200mg Cimzia syringe SC q 2 weeks

DRUG

Placebo

prefilled saline syringe

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Michael Schiff, MD

    lead INDIV

Principal Investigators

  • Michael H Schiff, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147341 on ClinicalTrials.gov